Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

Background: Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression might predict the benefit of bevacizumab treatment in pati...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Medical Oncology
Main Authors:	Daniela Bianconi, Merima Herac, Florian Posch, Margit Schmeidl, Matthias Unseld, Markus Kieler, Robert Brettner, Leonhard Müllauer, Jakob Riedl, Armin Gerger, Werner Scheithauer, Gerald Prager
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-08-01
Online Access:	https://doi.org/10.1177/1758835920928635